Universitat Pompeu Fabra-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2020

  1. A new risk variant for multiple sclerosis at 11q23.3 locus is associated with expansion of CXCR5+ circulating regulatory T cells

    Journal of Clinical Medicine, Vol. 9, Núm. 3

2016

  1. Possible therapeutic doses of cannabinoid type 1 receptor antagonist reverses key alterations in fragile X syndrome mouse model

    Genes, Vol. 7, Núm. 9

  2. Synaptic plasticity and spatial working memory are impaired in the CD mouse model of Williams-Beuren syndrome

    Molecular Brain, Vol. 9, Núm. 1

2015

  1. Pharmacogenomic study in patients with multiple sclerosis Responders and nonresponders to IFN-β

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 2, Núm. 5, pp. e154

2013

  1. Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis

    Journal of Medical Genetics, Vol. 50, Núm. 1, pp. 25-33

  2. Targeting the endocannabinoid system in the treatment of fragile X syndrome

    Nature Medicine, Vol. 19, Núm. 5, pp. 603-607

2012

  1. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis

    Multiple Sclerosis Journal, Vol. 18, Núm. 7, pp. 983-990

2011

  1. IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis

    Journal of Neuroimmunology, Vol. 239, Núm. 1-2, pp. 101-104

2007

  1. CB1 knockout mice display impaired functionality of 5-HT 1A and 5-HT2A/C receptors

    Journal of Neurochemistry, Vol. 103, Núm. 5, pp. 2111-2120